Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease
Authors: Meir Schechter, Glenn M. Chertow, Hiddo J.L. Heerspink
Journal: Annals of Internal Medicine (2023)

LettersJuly 2023Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney DiseaseMeir Schechter, MD, Glenn M. Chertow, MD, Hiddo J.L. Heerspink, PhDMeir Schechter, MDDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel, and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel, Glenn M. Chertow, MDDepartment of Medicine and Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California, Hiddo J.L. Heerspink, PhDDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, and The George Institute for Global Health, Sydney, New South Wales, AustraliaAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L23-0070 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE: We thank Dr. Patoulias for proposing to further explore dapagliflozin's effect on the rate of hospitalizations due to neoplasms in the DAPA-CKD trial. These are intriguing subgroup analyses, and we will consider performing them in the future. Author, Article, and Disclosure InformationAuthors: Meir Schechter, MD; Glenn M. Chertow, MD; Hiddo J.L. Heerspink, PhDAffiliations: Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel, and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, IsraelDepartment of Medicine and Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CaliforniaDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, and The George Institute for Global Health, Sydney, New South Wales, AustraliaDisclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M22-2115. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEffects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease Meir Schechter , Niels Jongs , Glenn M. Chertow , Ofri Mosenzon , John J.V. McMurray , Ricardo Correa-Rotter , Peter Rossing , Anna Maria Langkilde , C. David Sjöström , Robert D. Toto , David C. Wheeler , and Hiddo J.L. Heerspink Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease Dimitrios Patoulias Metrics July 2023Volume 176, Issue 7KeywordsCardiology and cardiovascular diseasesClinical trialsEstimated glomerular filtration rateHealth careHeart failureHospitalizationsKidneysRandomized trialsSodium-glucose contransporter-2 inhibitorsType 2 diabetes ePublished: 18 July 2023 Issue Published: July 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...